Sustained ventricular tachycardia and its successful prophylaxis during high-dose bolus interleukin-2 therapy for metastatic renal cell carcinoma

被引：1
作者：
Oleksowicz, L
Escott, P
Leichman, GC
Spangenthal, E
机构：
[1] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA
[2] SUNY Buffalo, Sch Med, Buffalo Gen Hosp, Dept Cardiol, Buffalo, NY USA
来源：
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2000年 / 23卷 / 01期
关键词：
ventricular tachycardia; interleukin-2; renal cell carcinoma;
D O I：
10.1097/00000421-200002000-00009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In the setting of interleukin-2 (IL-2) administration, tachycardias of ventricular origin are classified as serious, grade IV toxicities, necessitating the discontinuation of therapy. In this report, we describe a patient with renal cell carcinoma who experienced ventricular tachycardia while undergoing treatment with high-dose bolus IL-2. Prophylaxis with sotalol permitted the successful completion of his first cycle of treatment, without any recurrent rhythm disturbances.
引用
收藏
页码：34 / 36
页数：3
相关论文
共 21 条
  • [1] ARKINS MB, 1997, P AN M AM SOC CLIN, V16, P494
  • [2] RANDOMIZED PHASE-II TRIAL OF HIGH-DOSE INTERLEUKIN-2 EITHER ALONE OR IN COMBINATION WITH INTERFERON-ALFA-2B IN ADVANCED RENAL-CELL CARCINOMA
    ATKINS, MB
    SPARANO, J
    FISHER, RI
    WEISS, GR
    MARGOLIN, KA
    FINK, KI
    RUBINSTEIN, L
    LOUIE, A
    MIER, JW
    GUCALP, R
    SOSMAN, JA
    BOLDT, DH
    DOROSHOW, JH
    ARONSON, FR
    SZNOL, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) : 661 - 670
  • [3] BRADLEY EC, 1989, P AN M AM SOC CLIN, V8, P133
  • [4] RESULTS OF TREATMENT OF 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA WHO RECEIVED HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY
    FYFE, G
    FISHER, RI
    ROSENBERG, SA
    SZNOL, M
    PARKINSON, DR
    LOUIE, AC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) : 688 - 696
  • [5] Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy
    Fyfe, GA
    Fisher, RI
    Rosenberg, SA
    Sznol, M
    Parkinson, DR
    Louie, AC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (08) : 2410 - 2411
  • [6] THE HEMODYNAMIC-EFFECTS OF TREATMENT WITH INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER CELLS
    GAYNOR, ER
    VITEK, L
    STICKLIN, L
    CREEKMORE, SP
    FERRARO, ME
    THOMAS, JX
    FISHER, SG
    FISHER, RI
    [J]. ANNALS OF INTERNAL MEDICINE, 1988, 109 (12) : 953 - 958
  • [7] HOHNLOSER SH, 1994, NEW ENGL J MED, V331, P31
  • [8] LEE RE, 1989, J CLIN ONCOL, P7
  • [9] INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER CELL THERAPY OF SOLID TUMORS - ANALYSIS OF TOXICITY AND MANAGEMENT GUIDELINES
    MARGOLIN, KA
    RAYNER, AA
    HAWKINS, MJ
    ATKINS, MB
    DUTCHER, JP
    FISHER, RI
    WEISS, GR
    DOROSHOW, JH
    JAFFE, HS
    ROPER, M
    PARKINSON, DR
    WIERNIK, PH
    CREEKMORE, SP
    BOLDT, DH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (04) : 486 - 498
  • [10] TOXICITY OF IMMUNOTHERAPY WITH INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER CELLS
    MIER, JW
    ARONSON, FR
    NUMEROF, RP
    VACHINO, G
    ATKINS, MB
    [J]. PATHOLOGY AND IMMUNOPATHOLOGY RESEARCH, 1988, 7 (06): : 459 - 476
123